Back to search results

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Endometrial Cancer · Ovarian Cancer · Ovarian Cancer Metastatic · Ovarian Cancer Metastatic Recurrent · Non-squamous EGFR Wt NSCLC · Platinum Resistant Ovarian Cancer · PROC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Arkansas, Little Rock, Arkansas, United States

    Contact: Study coordinator (Michael Birrer, MD) · MJbirrer@uams.edu
    Contact: Principal Investigator (Michael Birrer, MD)

  • UCLA - Hematology/Oncology Clinical Research Unit, Los Angeles, California, United States

    Contact: Study coordinator (Aaron Lisberg, MD) · alisberg@mednet.ucla.edu · 310-352-8252
    Contact: Principal Investigator (Aaron Lisberg, MD)

  • St. Francis Medical Center (OSF Healthcare), Peoria, Illinois, United States

    Contact: Study coordinator (Michelle C Rowland, MD) · michelle.rowland@osfhealthcare.org · 309-308-3350
    Contact: Principal Investigator (Michelle Rowland, MD)

  • START - Midwest, Grand Rapids, Michigan, United States

    Contact: Study coordinator (Manish Sharma, MD) · manish.sharma@startresearch.com · 616-954-5554
    Contact: Principal Investigator (Manish Sharma)

  • Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States

    Contact: Study coordinator (Oncology Clinical Research Referral Office) · oncologyresearchreferral@hmhn.org · 551-996-1777
    Contact: Principal Investigator (Miguel Gonzalez, MD)

  • Roswell Park Comprehensive Care Center, Buffalo, New York, United States

    Contact: Study coordinator (Bailey Fitzgerald, MD) · bailey.fitzgerald@roswellpark.org · 716-845-2300
    Contact: Principal Investigator (Bailey Fitzgerald, MD)

  • University Hospital - Cleveland Medical Center, Cleveland, Ohio, United States

    Contact: Study coordinator (Matthew C Mirsky, MD) · Matthew.Mirsky2@UHhospitals.org · 301-980-8969
    C
    Contact: Principal Investigator (Matthew MIrsky, MD)

  • NEXT Oncology - Austin, Austin, Texas, United States

    Contact: Study coordinator (Sheena Sahota, MD) · ssahota@nextoncology.com · 737-610-5200

  • NEXT - Oncology - Houston, Houston, Texas, United States

    Contact: Study coordinator (Jennifer Segar, MD) · jsegar@nextoncology.com · 832-384-7900
    Contact: Principal Investigator (Jennifer Segar, MD)

  • START - San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Drew Rasco, MD) · drew.rasco@startresearch.com · 210-593-5258

  • NEXT Oncology - Virginia Cancer Specialists, Fairfax, Virginia, United States

    Contact: Study coordinator (Alexander Spira, MD, PhD) · aspira@nextoncology.com · 571-350-8400
    Contact: Principal Investigator (Alexander Spira, MD, PhD)

  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Lei C Deng, MD) · ldeng1@fredhutch.org · 206-606-4801
    C
    Contact: Principal Investigator (Lei Deng, MD)
Study leads

  • Margaret C Dugan, MD

    Study Director

    Whitehawk Therapeutics

  • Edward C Spindler, BS, MBA

    Study Director

    Whitehawk Therapeutics

View source on ClinicalTrials.gov(opens in a new tab)